[ad_1]
SAN DIEGO, Aug. 18, 2023 /PRNewswire/ — The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sage Therapeutics, Inc. SAGE focused on whether Sage Therapeutics and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.
http://www.rgrdlaw.com for more information. (PRNewsFoto/Robbins Geller Rudman & Dowd LLP)” alt=”Robbins Geller, with 200 lawyers in ten offices, represents U.S. and international institutional investors in contingency-based securities and corporate litigation. The firm has obtained many of the largest securities class action recoveries in history, including the largest securities class action judgment. Please visit http://www.rgrdlaw.com for more information. (PRNewsFoto/Robbins Geller Rudman & Dowd LLP)”>
If you have information that could assist in this investigation or if you are a Sage Therapeutics investor who suffered a loss and would like to learn more, you can provide your information here:
https://www.rgrdlaw.com/cases-sage-therapeutics-inc-investigation-sage.html
You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com.
THE COMPANY: Sage Therapeutics is a biopharmaceutical company that develops and commercializes brain health medicines. On December 6, 2022, Sage Therapeutics and Biogen Inc. announced the completion of the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for zuranolone in the treatment of major depressive disorder (“MDD”) and postpartum depression (“PPD”). Zuranolone is an investigational drug being evaluated as a rapid-acting, once-daily, 14-day oral short course treatment in adults with MDD and PPD.
THE REVELATION: On August 4, 2023, Sage Therapeutics disclosed that “the…
[ad_2]
